[1]范芯铷,刘铭佳,王庆,等.原发性肝癌的发病机制及治疗进展[J].肝脏,2023,28(4):391-392.
FAN XR,LIU MJ,WANG Q,et al.The pathogenesis and treatment progress of primary liver cancer[J].Chinese Hepatology,2023,28(4):391-392.
[2]中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南(2022年版)[J].肿瘤防治研究,2022,49(3):251-276.
National Health Commission of the People's Republic of China.Standardization for diagnosis and treatment of primary hepatic carcinoma(2022 edition)[J].Cancer Research on Prevention and Treatment,2022,49(3):251-276.
[3]HE J,WANG T,LI Y,et al.Dynamic chaotic gravitational search algorithm-based kinetic parameter estimation of hepatocellular carcinoma on(18)F-FDG PET/CT[J].BMC Med Imaging,2022,22(1):20.
[4]GEIST BK,XING H,WANG J,et al.A methodological investigation of healthy tissue,hepatocellular carcinoma,andother lesions with dynamic (68)Ga-FAPI-04 PET/CT imaging[J].EJNMMI Phys,2021,8(1):8.
[5]WANG H,MIAO Y,YU W,et al.Improved clinical workflow for whole-body patlak parametric imaging using two short dynamic acquisitions[J].Front Oncol,2022,12:822708.
[6]孔俊峰,逯自明,郑浩,等.血清AFP、CEA、CA-199、CA-125联合检测对原发性肝癌的诊断价值[J].临床医学,2023,43(4):82-84.
KONG JF,LU ZM,ZHENG H,et al.Combined detection of serum AFP,CEA,CA-199,and CA-125 for primary liver cancerdiagnostic value[J].Clinical Medicine,2023,43(4):82-84.
[7]FREESMEYER M,GREISER J,WINKENS T,et al.Dynamic PET/CT with the hepatobiliary tracer[68Ga]Ga-Tmos-DAZA for characterization of a hepatic tumor[J].Diagnostics(Basel),2021,11(4):660.
[8]SKAWRAN S,MESSERLI M,KOTASIDIS F,et al.Can dynamic whole-body FDG PET imaging differentiate between malignant and inflammatory lesions[J].Life(Basel),2022,12(9):1350.
[9]TSURUSAKI M,OKADA M,KURODA H,et al.Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor[J].J Gastroenterol,2014,49(1):46-56.
[10]WANGERIN KA,MUZI M,PETERSON LM,et al.A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy[J].Phys Med Biol,2017,62(9):3639-3655.
[11]TONG X,SRIVATSAN A,JACOBSON O,et al.Monitoring tumor hypoxia using (18)F-FMISO PET and pharmacokinetics modeling after photodynamic therapy[J].Sci Rep,2016,6:31551.
[12]TSUCHIDA T,SADATO N,YONEKURA Y,et al.Noninvasive measurement of cerebral metabolic rate of glucose using standardized input function[J].J Nucl Med,1999,40(9):1441-1445.
[13]UNZUETA A,CABRERA R.Treatment options in patients awaiting liver transplantation with hepatocellular carcinoma and cholangiocarcinoma[J].Clin Liver Dis,2017,21(2):231-251.
[14]VISSER EP,PHILIPPENS ME,KIENHORST L,et al.Comparison of tumor volumes derived from glucose metabolic rate maps and SUV mapsin dynamic 18F-FDG PET[J].J Nucl Med,2008,49(6):892-898.
[15]李天然,雷勇,宋斌,等.肝癌细胞FDG摄取与葡萄糖转运蛋白相关性的实验研究[J].胃肠病学和肝病学杂志,2012,21(7):589-593.
LI TR,LEI Y,SONG B,et al.The correlation of hepatocellular carcinoma cells uptake FDG and glucose transporters[J].Chinese Journal of Gastroenterology and Hepatology,2012,21(7):589-593.
[16]WANG SB,WU HB,WANG QS,et al.Combined early dynamic (18)F-FDG PET/CT and conventional whole-body (18)F-FDG PET/CT provide one-stop imaging for detecting hepatocellular carcinoma[J].Clin Res Hepatol Gastroenterol,2015,39(3):324-330.
[17]王祖飞,兰茜琳,肖扬锐,等.原发性胆管癌TNM分期与18F-脱氧葡萄糖正电子发射计算机断层扫描最大标准摄取值的相关性[J].中华医学杂志,2017,97(39):3104-3107.
WANG ZF,LAN XL,XIAO YR,et al.Correlation between TNM staging of primary cholangiocarcinoma and the maximum standard uptake value of 18F-2-deoxy-D-glucose positron emission tomography with computerized tomography[J].National Medical Journal of China,2017,97(39):3104-3107.